Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

In Vitro and In Vivo Antitumor and Anti-Inflammatory Capabilities of the Novel GSK3 and CDK9 Inhibitor ABC1183.

Schrecengost RS, Green CL, Zhuang Y, Keller SN, Smith RA, Maines LW, Smith CD.

J Pharmacol Exp Ther. 2018 Apr;365(1):107-116. doi: 10.1124/jpet.117.245738. Epub 2018 Feb 6.

PMID:
29434052
2.

Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.

Schrecengost RS, Keller SN, Schiewer MJ, Knudsen KE, Smith CD.

Mol Cancer Res. 2015 Dec;13(12):1591-601. doi: 10.1158/1541-7786.MCR-14-0626. Epub 2015 Aug 13.

3.

USP22 regulates oncogenic signaling pathways to drive lethal cancer progression.

Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ, Urban MW, Stanek TJ, Sussman RT, Hicks JL, Birbe RC, Draganova-Tacheva RA, Visakorpi T, DeMarzo AM, McMahon SB, Knudsen KE.

Cancer Res. 2014 Jan 1;74(1):272-86. doi: 10.1158/0008-5472.CAN-13-1954. Epub 2013 Nov 6.

4.

A hormone-DNA repair circuit governs the response to genotoxic insult.

Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, Ma T, Den RB, Dicker AP, Feng FY, Knudsen KE.

Cancer Discov. 2013 Nov;3(11):1254-71. doi: 10.1158/2159-8290.CD-13-0108. Epub 2013 Sep 11.

5.

Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells.

Wilson AL, Schrecengost RS, Guerrero MS, Thomas KS, Bouton AH.

PLoS One. 2013 Jun 6;8(6):e65678. doi: 10.1371/journal.pone.0065678. Print 2013.

6.

BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling.

Schuh NR, Guerrero MS, Schrecengost RS, Bouton AH.

J Biol Chem. 2010 Jan 22;285(4):2309-17. doi: 10.1074/jbc.M109.046631. Epub 2009 Nov 23.

7.

The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines.

Deacon DH, Hogan KT, Swanson EM, Chianese-Bullock KA, Denlinger CE, Czarkowski AR, Schrecengost RS, Patterson JW, Teague MW, Slingluff CL Jr.

BMC Cancer. 2008 Dec 4;8:360. doi: 10.1186/1471-2407-8-360.

8.

A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells.

Ta HQ, Thomas KS, Schrecengost RS, Bouton AH.

Cancer Res. 2008 Nov 1;68(21):8796-804. doi: 10.1158/0008-5472.CAN-08-2426.

9.
10.

Pathways to tamoxifen resistance.

Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH.

Cancer Lett. 2007 Oct 18;256(1):1-24. Epub 2007 May 1. Review.

11.

Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients.

Cragun WC, Yamshchikov GV, Bissonette EA, Smolkin ME, Eastham S, Petroni GR, Schrecengost RS, Woodson EM, Slingluff CL Jr.

Cancer Immunol Immunother. 2005 Nov;54(11):1095-105. Epub 2005 May 12.

PMID:
15889250
12.

Cyclohexyl-octahydro-pyrrolo[1,2-a]pyrazine-based inhibitors of human N-myristoyltransferase-1.

French KJ, Zhuang Y, Schrecengost RS, Copper JE, Xia Z, Smith CD.

J Pharmacol Exp Ther. 2004 Apr;309(1):340-7. Epub 2004 Jan 14.

13.

Discovery and evaluation of inhibitors of human sphingosine kinase.

French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK, Smith CD.

Cancer Res. 2003 Sep 15;63(18):5962-9.

Supplemental Content

Loading ...
Support Center